Akademik Veri Yönetim Sistemi
Türk Toraks Derneği 21. Yıllık Kongresi, Antalya, Türkiye, 12 - 15 Nisan 2018, ss.278
Background and aim: Recently, antifibrotic therapy has been approved in idiopathic pulmonary fibrosis (IPF). In this study, we aimed to
evaluate the effectiveness, safety, and tolerability of pirfenidone therapy in our
patients with IPF.
Methods: In this retrospective study, we were evaluated 60 IPF patients who were taking pirfenidone at least for 6 months. IPF was diagnosed by clinical and radiology and/or histopathology. Patient characteristics, symptoms, pulmonary function tests (FVC, DLCO), 6-minute walk
test (6-MWT), and effectiveness of therapy (stability or progression of the
disease defined as a decline of FVC (%pred.) ≥10%) at baseline and after
6 months of drug therapy), side effects, any hospitalization and mortality
were recorded
Results: Of 60 IPF patients, 44 (73,4%) were male. While 46 (76,7%)
IPF patients were stable during the therapy course, 14 (23,3%) IPF patients
had progressed according to decline in FVC ≥ 10%. During 6 months
of antifibrotic therapy, in 9 (15,0%) IPF patients had an exacerbation, and
in 10 (16,7%) patients had all-cause hospitalization, and one (1,7%) patient died. At least one side effect due to therapy were encountered in 33
(55,0%) IPF patients. Leading side effects were gastrointestinal symptoms
(n=21, 35,0%) and photosensitivity (n=8, 13,3%). While in 16 (26,7%)
patients, therapy dose was decreased, in only one (1,7%) patients therapy
was discontinued due to intolerability.
Conclusions: We concluded that pirfenidone therapy for IPF was effective and tolerable, and also had relatively acceptable side effects in our
patients with IPF